dc.contributor.author | Ffytche, DH | |
dc.contributor.author | Creese, B | |
dc.contributor.author | Politis, M | |
dc.contributor.author | Chaudhuri, KR | |
dc.contributor.author | Weintraub, D | |
dc.contributor.author | Ballard, C | |
dc.contributor.author | Aarsland, D | |
dc.date.accessioned | 2020-02-03T11:50:43Z | |
dc.date.issued | 2017-01-20 | |
dc.description.abstract | In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD psychosis, and the causal and modifying effects of PD medication. We discuss recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages. In addition, we highlight novel risk factors-for example, autonomic dysfunction-that have emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The accumulating evidence raises novel questions and directions for future research to explore the clinical management and biomarker potential of PD psychosis. | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.identifier.citation | Vol. 13, pp. 81 - 95 | en_GB |
dc.identifier.doi | 10.1038/nrneurol.2016.200 | |
dc.identifier.grantnumber | SHAPED RP-PG-0610-10100 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/40704 | |
dc.language.iso | en | en_GB |
dc.publisher | Nature Research | en_GB |
dc.rights | © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.. | en_GB |
dc.title | The psychosis spectrum in Parkinson disease | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2020-02-03T11:50:43Z | |
dc.identifier.issn | 1759-4758 | |
dc.description | This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record | en_GB |
dc.identifier.journal | Nature Reviews Neurology | en_GB |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
dcterms.dateAccepted | 2017-01-20 | |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2017-02-01 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2020-02-03T11:41:34Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2020-02-03T11:50:49Z | |
refterms.panel | A | en_GB |